The FNAME yields equivalent results differentiating amnestic mild cognitive impairment from subjective cognitive decline and healthy controls in Mexico and the Netherlands ; Neuropsychiatry and behavioral neurology/Mild cognitive impairment/Early symptomatic disease
Abstract Background The Face‐Name Associative Memory Exam (FNAME) has been shown to detect memory deficits early in the spectrum of Alzheimer’s disease. In this study, we used a newly developed and further extended version of the FNAME, to evaluate the discriminating ability of this test in amnestic cognitive decline (aMCI), amnestic subjective cognitive decline (aSMD), and healthy controls (HC) in two different cultures, namely Mexico and the Netherlands. Method Participants were recruited in two sites, in Mexico (n= 69) and the Netherlands (n= 55). The mean age of the subjects was 69.3 ±6 ye... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Reihe/Periodikum: | Alzheimer's & Dementia ; volume 16, issue S6 ; ISSN 1552-5260 1552-5279 |
Verlag/Hrsg.: |
Wiley
|
Schlagwörter: | Psychiatry and Mental health / Cellular and Molecular Neuroscience / Geriatrics and Gerontology / Neurology (clinical) / Developmental Neuroscience / Health Policy / Epidemiology |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26850878 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1002/alz.044333 |